INT74614

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1998
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 16
Total Number 22
Disease Relevance 23.95
Pain Relevance 5.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa1) transport (Apoa1) extracellular space (Apoa1)
extracellular region (Apoa1) nucleus (Apoa1) enzyme binding (Apoa1)
Anatomy Link Frequency
plasma 1
sciatic nerves 1
cerebral spinal fluid 1
astrocytes 1
Apoa1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 336 99.84 Very High Very High Very High
Demyelination 14 98.98 Very High Very High Very High
Sciatic nerve 7 98.24 Very High Very High Very High
Inflammation 67 98.06 Very High Very High Very High
Central nervous system 49 97.80 Very High Very High Very High
depression 5 96.20 Very High Very High Very High
Inflammatory response 8 95.06 Very High Very High Very High
rheumatoid arthritis 119 93.24 High High
cytokine 56 92.00 High High
Pain 8 90.56 High High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 423 100.00 Very High Very High Very High
Demyelinating Disease 413 99.84 Very High Very High Very High
Nicotine Addiction 14 99.80 Very High Very High Very High
Systemic Lupus Erythematosus 133 99.32 Very High Very High Very High
Metabolic Syndrome 125 99.32 Very High Very High Very High
Disease 103 98.24 Very High Very High Very High
INFLAMMATION 78 98.06 Very High Very High Very High
Peripheral Arterial Disease 13 97.60 Very High Very High Very High
Syndrome 100 97.32 Very High Very High Very High
Myocardial Infarction 97 97.26 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recently, Gaillard et al conformed that the decreasing CSF (cerebral spinal fluid) apo E (apolipoprotein E) concentrations in MS patients as apoE was postulated to be a major lipid carrier protein [23], therefore, we wonder if the CSF apoA-I concentrations would be increased in MS patients, our next task is to conform the hypothesis.
Positive_regulation (increased) of apoA-I in cerebral spinal fluid associated with multiple sclerosis and disorder of lipid metabolism
1) Confidence 0.68 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.06 Pain Relevance 0.74
In recent years, some researchers conformed that astrocytes generated apoA-I and apoE in rat, apoA-I facilitated translocation of newly synthesized cholesterol and phospholipid to cytosol to form the lipid-protein complex particles as an initial event in cholesterol trafficking for the assembly of HDL, and found cholesterol efflux from rat astrocytes induced by apoA-I and apoE.
Positive_regulation (generated) of apoA-I in astrocytes associated with disorder of lipid metabolism
2) Confidence 0.68 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 0.88 Pain Relevance 0.30
In order to clarify the effect of CNS inflammatory response on serum apoA-I levels, we compare neuroinflammation patients with MS patients, This study further confirmed that, compared to other CNS inflammatory diseases, the imbalance between demyelination and regeneration in MS patients may be related to elevated serum apoA-I concentrations.
Positive_regulation (elevated) of apoA-I associated with demyelination, multiple sclerosis, inflammatory response, inflammation, central nervous system and disease
3) Confidence 0.68 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.74 Pain Relevance 0.79
In the study, our data showed elevated serum apoA-I concentrations in MS patients may be an important feature that is different from other autoimmune diseases which had significantly reduced serum apoA-I levels (such as RA and SLE).
Positive_regulation (elevated) of apoA-I associated with multiple sclerosis, autoimmune disease, rheumatoid arthritis and systemic lupus erythematosus
4) Confidence 0.49 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.26 Pain Relevance 0.56
Similar to the Shore ea al, our research showed increased serum apoA-I levels in MS patients and other autoimmune demyelinating disease (CIS, GBS) whether male and female patients.
Spec (whether) Positive_regulation (increased) of apoA-I associated with multiple sclerosis, syndrome and demyelinating disease
5) Confidence 0.46 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.10 Pain Relevance 0.61
They found apoA-I had increased 26-fold in rat homogenates of regenerating sciatic nerves within 3 weeks after injury [35].
Positive_regulation (increased) of apoA-I in sciatic nerves associated with injury and sciatic nerve
6) Confidence 0.46 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 0.97 Pain Relevance 0.40
Serum apoA-I levels was significantly elevated in female MS patients (P = 0.033; P < 0.05).


Positive_regulation (elevated) of apoA-I associated with multiple sclerosis
7) Confidence 0.46 Published 2010 Journal Lipids Health Dis Section Abstract Doc Link PMC2860353 Disease Relevance 1.78 Pain Relevance 0.38
With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P<0.002) increase in the apoA1 to apoB ratio.
Positive_regulation (increased) of apoA1
8) Confidence 0.22 Published 1998 Journal Arterioscler. Thromb. Vasc. Biol. Section Abstract Doc Link 9848888 Disease Relevance 0.88 Pain Relevance 0.39
With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P<0.002) increase in the apoA1 to apoB ratio.
Positive_regulation (increase) of apoA1
9) Confidence 0.15 Published 1998 Journal Arterioscler. Thromb. Vasc. Biol. Section Abstract Doc Link 9848888 Disease Relevance 0.86 Pain Relevance 0.39
Results showed that only toremifene had a beneficial effect on lipid profile, indicated by a decrease in total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B, and an increase in HDL cholesterol and apolipoprotein A1.
Positive_regulation (increase) of apolipoprotein A1 associated with disorder of lipid metabolism
10) Confidence 0.12 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001222 Disease Relevance 1.01 Pain Relevance 0
44%) and increase in the apoA1/apoB ratio (?
Positive_regulation (increase) of apoA1
11) Confidence 0.09 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 0.46 Pain Relevance 0
This study also shows that there is increasing efficacy of this drug combination and a trend towards a continued decline in LDL cholesterol, triglycerides, and lp(a), and an increase in HDL cholesterol and apoA1.
Positive_regulation (increase) of apoA1 associated with disorder of lipid metabolism
12) Confidence 0.08 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 0.40 Pain Relevance 0
HDL cholesterol and apoA1/apoB increased by 7.2%, 13.1%, and 18.2%; and 7.9, 21.9 and 51.6% respectively (p < 0.01) (Figure 1).
Positive_regulation (increased) of apoA1 associated with disorder of lipid metabolism
13) Confidence 0.08 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 0.98 Pain Relevance 0.06
HDL cholesterol and apoA1/apoB increased by 7.2%, 13.1%, and 18.2%; and 7.9%, 21.9%, and 51.6% respectively (p < 0.01).
Positive_regulation (increased) of apoA1 associated with disorder of lipid metabolism
14) Confidence 0.08 Published 2006 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC1993969 Disease Relevance 0.72 Pain Relevance 0.03
Lovastatin and niacin in low doses used in the present study resulted in a significant decline in LDL cholesterol, triglycerides, and lp(a) along with an increase in HDL cholesterol and apoA1/apoB ratio.
Positive_regulation (increase) of apoA1 associated with disorder of lipid metabolism
15) Confidence 0.08 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 1.34 Pain Relevance 0.10
Greater improvements in ApoA-I and the ApoB/ApoA-I ratio were also seen in the rosuvastatin 10 mg group compared with the atorvastatin 20 mg group (p < 0.001, p = 0.001, respectively), while reductions in ApoB were similar between treatments (Table 2).


Positive_regulation (improvements) of ApoA-I
16) Confidence 0.07 Published 2006 Journal Trials Section Body Doc Link PMC1779361 Disease Relevance 0.59 Pain Relevance 0
Greater improvements in ApoA-I and the ApoB/ApoA-I ratio were also seen in the rosuvastatin 10 mg group compared with the atorvastatin 20 mg group (p < 0.001, p = 0.001, respectively), while reductions in ApoB were similar between treatments (Table 2).


Positive_regulation (improvements) of ApoA-I
17) Confidence 0.07 Published 2006 Journal Trials Section Body Doc Link PMC1779361 Disease Relevance 0.59 Pain Relevance 0
Importantly, the rise in triglyceride with colesevelam was accompanied by a reduction in LDL cholesterol (16.7%) and apoB (6.7%) and an increase in apoA-I concentration (3.8%, P < 0.001 vs. placebo for LDL cholesterol, apoB, and apoA-I).
Positive_regulation (increase) of apoA-I
18) Confidence 0.04 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0.37 Pain Relevance 0.16
It is the country with lowest mean age at incidence of AMI, and among INTERHEART control subjects, it has the highest prevalence of most risk factors studied: current and former smoking (59.9%), elevated apolipoprotein B100 (ApoB100)/apolipoprotein A-I (ApoA-I) ratio (59.7%), abdominal obesity (43.3%), self-reported history of hypertension (14.3%), and depression (43.0%).
Positive_regulation (elevated) of ApoA-I associated with nicotine addiction, depression, hypertension, metabolic syndrome, disorder of lipid metabolism and myocardial infarction
19) Confidence 0.02 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2742703 Disease Relevance 1.02 Pain Relevance 0.05
We conclude that the dyslipidemic profile characterized by increased triglyceride level, decreased apolipoprotein A1 level and small dense LDL is associated with uncomplicated PVD in both NIDDM and non-diabetic subjects.
Positive_regulation (increased) of apolipoprotein A1 associated with diabetes mellitus, peripheral arterial disease and disorder of lipid metabolism
20) Confidence 0.02 Published 1998 Journal Atherosclerosis Section Abstract Doc Link 9544725 Disease Relevance 2.03 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox